Revvityブログ
発見から治療までのイノベーションを促進
 
     
    
            
        Latest
      
    
    Optimizing functional genomics research tools by aligning their design with the ongoing evolution of the genome.
Functional Genomic Screening 
October 30, 2025  -  3  min read
       
      Reproductive Health
        Uniting for early detection: the role of Revvity in DMD screening.
            August 16, 2025 -
            6 min read
          
          
         
      Cancer
        How conditional bispecific antibodies are advancing precision immunotherapy.
            August 14, 2025 -
            2 min read
          
          
         
       
      Cancer
        Scaling up oligonucleotide discovery: accelerating therapeutic lead identification from months to weeks.
            August 6, 2025 -
            3 min read
          
          
         
      Functional Genomic Screening
        Building on Ambros and Ruvkun's Nobel-Winning studies with Revvity’s microRNA toolkit.
            July 30, 2025 -
            3 min read
          
          
         
      Disease Research
        What to consider when choosing a homogenizer for your lab.
            July 30, 2025 -
            3 min read
          
          
         
      NGS
        Cell-free DNA: dynamic regulation and NGS strategies for ultra-low-frequency variant detection.
            July 28, 2025 -
            7 min read
          
          
         
       
      Functional Genomic Screening
        Exploring the importance of sequencing guide RNAs in Functional Genomics.
            July 28, 2025 -
            5 min read
          
          
         
       
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                  